BioSpace News Archive

Biotech Beach

Progenity to Become Biora Therapeutics as it Completes Transformation

Progenity, Inc. announced that it will change its name to Biora Therapeutics, Inc. during the second quarter of 2022, to better reflect the company’s focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics.

April 12, 2022
·
1 min read
BioMidwest

Gb Sciences to Begin Dosage Study for Its Novel Parkinson’s Disease Formulations at the University of Lethbridge

Gb Sciences, Inc., a leading plant-inspired biopharmaceutical research and development company, has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences’ patent-protected formulations in a rodent model of Parkinson’s disease.

April 12, 2022
·
7 min read
Genetown

Akston Biosciences CEO to Present at the World Vaccine Congress - Apr 12, 2022

Akston Biosciences Corporation, a developer of new classes of biologics, announced that its president and CEO, Todd Zion, Ph.D., has been invited to present at this year’s World Vaccine Congress.

April 12, 2022
·
3 min read
Business

Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa

Actinium Pharmaceuticals, Inc. and Immedica Pharma AB (“Immedica”) today announced entering a license and supply agreement for Iomab-B,

April 12, 2022
·
9 min read
Genetown

The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactive’s Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults with Major Depressive Disorder When Combined with Antidepressant Medication

The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactive’s Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults with Major Depressive Disorder When Combined with Antidepressant Medication.

April 12, 2022
·
15 min read
Genetown

Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform

Design Pharmaceuticals today announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners.

April 12, 2022
·
2 min read
Business

Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced clinical manufacturing expansion in the United Kingdom and the United States.

April 12, 2022
·
4 min read
Drug Development

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

Harpoon Therapeutics, Inc. today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting being held in New Orleans from April 8-13, 2022.

April 12, 2022
·
6 min read
Drug Development

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical trial evaluating CHK-336 in adult healthy volunteers.

April 12, 2022
·
5 min read
Bio NC

ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®Two Phase 3 controlled trials with substantially similar design to enroll 1,200 subjects with diabetic CKD

ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced the updated design for its REACT® Phase 3 program.

April 12, 2022
·
9 min read